People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

What this study is testing ClinicalTrials.gov NCT07207148 ↗

Description as written by the study sponsor.

The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score.

Treatments tested

• GLP-1 also known as Glucagon-like peptide-1, GLP-1 Agonist Drug

  Glucagon-like peptide-1 agonist agent is the study agent of interest. This study will not supply the GLP-1 drug but depends on the patient's clinical prescription of this drug.

• Ocrelizumab (US) also known as Ocrevus Drug

  All participants will be treated with Ocrelizumab for the indication of MS; however, the study will not provide Ocrelizumab as it will be part of the participant's routine clinical care.